Dexlansoprazole

The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.

Also Known As:

2-((R)-((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; Dexilant; Dexlansoprazole Sesquihydrate; Lansoprazole, R-Isomer; R-Lansoprazole; T-168390; TAK 390MR; TAK-390; TAK-390MR; TAK390MR; Lansoprazole, R Isomer; R Lansoprazole; R-Isomer Lansoprazole; T 168390; T168390; TAK 390; TAK390

Networked: 65 relevant articles (17 outcomes, 17 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Perez, M C: 6 articles (11/2013 - 04/2009)
2.	Perez, Maria Claudia: 4 articles (01/2019 - 01/2012)
3.	Wu, Deng-Chyang: 4 articles (01/2019 - 03/2016)
4.	Fass, Ronnie: 4 articles (02/2017 - 03/2011)
5.	Atkinson, S N: 4 articles (02/2011 - 04/2009)
6.	Chuah, Seng-Kee: 3 articles (01/2019 - 12/2017)
7.	Hsu, Pin-I: 3 articles (01/2019 - 12/2017)
8.	Huang, Chih-Fang: 3 articles (01/2019 - 12/2017)
9.	Kuo, Chao-Hung: 3 articles (01/2019 - 03/2016)
10.	Liang, Chih-Ming: 3 articles (01/2019 - 12/2017)

Related Diseases

1.	Heartburn (Pyrosis) 08/20/2010 - "In addition, the proportion of 24-hour heartburn-free days (primary endpoint) was significantly greater in recipients of dexlansoprazole MR 30 mg once daily than in recipients of placebo following 4 weeks' treatment in a large, randomized, double-blind, multicentre phase III trial in patients with NERD. " 11/01/2013 - "NERD patients receiving dexlansoprazole 30 and 60 mg experienced significantly greater improvements in symptom severity for both heartburn and regurgitation compared with placebo. " 06/15/2009 - "Dexlansoprazole MR provided significantly greater median percentages of 24-h heartburn-free days (54.9% and 50.0% for the 30- and 60-mg doses vs. 17.5% for placebo, P < 0.00001) and nights without heartburn (80.8% and 76.9% vs. 51.7%, P < 0.00001 vs. placebo). " 01/01/2019 - "Dexlansoprazole is effective in the treatment of heartburn during Ramadan. " 01/01/2019 - "Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan."
2.	Gastroesophageal Reflux (GERD) 01/30/2020 - "Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole." 02/01/2011 - "Twelve-month treatment with dexlansoprazole MR 60 and 90 mg was well tolerated by GERD patients in this study (Clinicaltrials.gov identifier NCT00255190)." 01/01/2022 - "Addendum: Dexlansoprazole for GERD." 01/01/2019 - "Dexlansoprazole has been shown to be efficacious for the treatment of gastroesophageal reflux disease. " 02/01/2017 - "The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease."
3.	Esophagitis 02/01/2017 - "Dexlansoprazole MR has been shown to be highly efficacious in healing erosive esophagitis, maintaining healed esophageal mucosa in patients with erosive esophagitis and controlling symptoms of patients with nonerosive reflux disease (NERD). " 07/30/2016 - "Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms. " 01/01/2019 - "Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents." 11/01/2011 - "Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data." 10/01/2016 - "Expert commentary: Overall, dexlansoprazole offers benefits in its ease of administration and proven efficacy in the healing, maintenance of erosive esophagitis, and symptomatic non-erosive GERD. "
4.	Non-Erosive Reflux Disease 08/20/2010 - "Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease." 10/01/2016 - "Expert commentary: Overall, dexlansoprazole offers benefits in its ease of administration and proven efficacy in the healing, maintenance of erosive esophagitis, and symptomatic non-erosive GERD. " 08/01/2011 - "When compared to placebo, dexlansoprazole provided significantly higher maintenance rates for healed esophageal mucosa in patients with erosive esophagitis and symptom control in patients with non-erosive reflux disease. " 07/01/2013 - "To compare the efficacy of dexlansoprazole with esomeprazole in healing erosive oesophagitis (EO), the maintenance of healed EO and the treatment of non-erosive reflux disease (NERD). " 01/30/2020 - "Since the use of dexlansoprazole in Asian subjects with gastroesophageal reflux disease (GERD) has not been adequately characterized, this study was conducted to evaluate the efficacy and safety of dexlansoprazole modified-release in Asian subjects with non-erosive reflux disease (NERD) and erosive esophagitis (EE). "
5.	Infections 02/01/2011 - "Of 591 patients receiving dexlansoprazole MR 60 and 90 mg, 71% and 65%, respectively, experienced ≥1 treatment-emergent AE; the most frequent AE was upper respiratory infection (14% and 13% in the 60- and 90-mg groups). " 01/01/2019 - "Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections." 03/01/2016 - "A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection." 03/01/2016 - "Since the pharmaceutical cost of the single-dose dexlansoprazole MR regime is lower than that of the double-dose rabeprazole regimen, dexlansoprazole-based therapy can reasonably be recommended in the first-line treatment of H pylori infection." 03/01/2016 - "This pilot, randomized, controlled, head-to-head study was conducted to investigate whether the efficacy of single-dose dexlansoprazole MR-based triple therapy was noninferior to double-dose rabeprazole-based triple therapy in the treatment of H pylori infection. "

Related Drugs and Biologics

1.	Lansoprazole (Prevacid)
2.	Proton Pump Inhibitors
3.	Esomeprazole (Nexium)
4.	Rabeprazole (Aciphex)
5.	Omeprazole (Prilosec)
6.	Pantoprazole (Protonix)
7.	Acids
8.	Vitamins
9.	Moxifloxacin (Avelox)
10.	Amoxicillin (Wymox)

Related Therapies and Procedures

1.	Therapeutics
2.	Duration of Therapy
3.	Sclerotherapy
4.	Ligation
5.	Stents